Cargando…
AR420626, a selective agonist of GPR41/FFA3, suppresses growth of hepatocellular carcinoma cells by inducing apoptosis via HDAC inhibition
BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide and establishment of new chemotherapies for HCC is urgently needed. GPR41 [free fatty acid receptor 3 (FFA3)] is a G protein-coupled receptor for short chain fatty acids, including acetate, propionate, and butyrate...
Autores principales: | Mikami, Daisuke, Kobayashi, Mamiko, Uwada, Junsuke, Yazawa, Takashi, Kamiyama, Kazuko, Nishimori, Kazuhisa, Nishikawa, Yudai, Nishikawa, Sho, Yokoi, Seiji, Taniguchi, Takanobu, Iwano, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517987/ https://www.ncbi.nlm.nih.gov/pubmed/33014144 http://dx.doi.org/10.1177/1758835920913432 |
Ejemplares similares
-
A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signaling pathways in HepG2 cells
por: Kobayashi, Mamiko, et al.
Publicado: (2018) -
Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets
por: Ulven, Trond
Publicado: (2012) -
Fanconi syndrome in an elderly patient with membranous nephropathy during treatment with the immunosuppressant mizoribine
por: Nishikawa, Sho, et al.
Publicado: (2022) -
The Specificity and Broad Multitarget Properties of Ligands for the Free Fatty Acid Receptors FFA3/GPR41 and FFA2/GPR43 and the Related Hydroxycarboxylic Acid Receptor HCA2/GPR109A
por: Bisenieks, Egils, et al.
Publicado: (2021) -
FFA4/GPR120: Pharmacology and Therapeutic Opportunities
por: Milligan, Graeme, et al.
Publicado: (2017)